Determinants of gastro-protective drugs co-prescription during treatment with nonselective NSAIDs: a prospective survey of 2197 patients recruited in primary care
[en] Objective: Our goal was to identify the magnitude of gastro-protective drugs (GPDs) co-prescription and the profile of patients who received GPD co-prescription, during nonsteroidal anti-inflammatory drugs (NSAIDs) treatment in a "real life setting" of primary care practice. Methods: A pragmatic prospective 6-month survey of 2197 new takers of nonselective NSAIDs, selected and followed by general practitioners (GPs) on the bias of their usual standards of care. Results: Forty-seven percent of our survey population used at least one GPD during the 6-month follow-up. No difference was identified between piroxicam, diclofenac, ibuprofen, meloxicam and nimesulid for the GPD co-prescription. Besides the presence of gastro-intestinal (GI) symptoms, previous use of GPD, previous occurrence of GI disorders and increase in age are the most prominent predictive factors of GPD use during NSAID treatment. When adjusted for other risk factors, co-prescription of GPD was significantly increased in patients aged 55 years and above (odds ratio (OR): 1.29, 95% confidence interval (Cl): 1.01-1.64) with no further increase in the co-prescription in older subjects. Conclusion: Patients above 55 years with previous history of GI symptoms or GPD use are more likely to benefit from cytoprotective medications. (C) 2006 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
Disciplines :
Rheumatology Orthopedics, rehabilitation & sports medicine
Author, co-author :
Rabenda, Véronique ; Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie et santé publique
Burlet, N.
Belaiche, Jacques ; Université de Liège - ULiège > Département des sciences cliniques > Hépato-gastroentérologie
Raeman, F.
Richy, F.
Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie et santé publique
Language :
English
Title :
Determinants of gastro-protective drugs co-prescription during treatment with nonselective NSAIDs: a prospective survey of 2197 patients recruited in primary care
Reginster J.Y. The prevalence and burden of arthritis. Rheumatology 41 Suppl 1 (2002) 3-6
Report of a WHO Scientific Group. The burden of musculoskeletal conditions at the start of the new millennium. WHO Technical Report Series 919. Geneva: World Health Organization, 2003; 1-218.
Macdonald T.M. Epidemiology and pharmacoeconomic implications of non-steroidal anti-inflammatory drug-associated gastrointestinal toxicity. Rheumatology (Oxford) 39 Suppl 2 (2000) 13-20
Spiegel B.M., Targownik L., Dulai G.S., and Gralnek I.M. The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis. Ann Intern Med 138 (2003) 795-806
Larkai E.N., Smith J.L., Lidsky M.D., and Graham D.Y. Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use. Am J Gastroenterol 82 (1987) 1153-1158
Lapane K.L., Spooner J.J., and Pettitt D. The effect of nonsteroidal anti-inflammatory drugs on the use of gastroprotective medication in people with arthritis. Am J Manag Care 7 (2001) 402-408
Bombardier C., Laine L., Reicin A., Shapiro D., Burgos-Vargas R., Davis B., et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 343 (2002) 1520-1528
Silverstein F.E., Faich G., Goldstein J.L., Simon L.S., Pincus T., Whelton A., et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 284 (2000) 1247-1255
Simon L.S., Hatoum H.T., Bittman R.M., Archambault W.T., and Polisson R.P. Risk factors for serious nonsteroidal-induced gastrointestinal complications: regression analysis of the MUCOSA trial. Fam Med 28 (1996) 204-210
Graham D.Y., Agrawal N.M., and Roth S.H. Prevention of NSAID-induced gastric ulcer with misoprostol: multicentre, double-blind, placebo-controlled trial. Lancet 2 (1988) 1277-1280
Wolfe M.M., Lichtenstein D.R., and Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 340 (1999) 1888-1899
La Corte R., Caselli M., Castellino G., Bajocchi G., and Trotta F. Prophylaxis and treatment of NSAID-induced gastroduodenal disorders. Drug Saf 20 (1999) 527-543
van Dijk K.N., ter Huurne K., de Vries C.S., van den Berg P.B., Brouwers J.R., and de Jong-van den Berg L.T. Prescribing of gastroprotective drugs among elderly NSAID users in the Netherlands. Pharm World Sci 24 (2002) 100-103
Belaiche J., Burette A., De Vos M., Louis E., Huybrechts M., and Deltenre M. Belgian Study Group of NSAID-GI Complications. Observational survey of NSAID-related upper gastro-intestinal adverse events in Belgium. Acta Gastroenterol Belg 55 (2002) 65-73
Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology 120 (2001) 594-606
Moore R.A., and Phillips C.J. Cost of NSAID adverse effects to the UK National Health Service. J Med Econ 2 (1999) 45-55
Solomon D.H., Glynn R.J., Bohn R., Levin R., and Avorn J. The hidden cost of nonselective nonsteroidal anti-inflammatory drugs in older patients. J Rheumatol 30 (2003) 792-798
Wiklund I. Quality of life in arthritis patients using nonsteroidal anti-inflammatory drugs. Can J Gastroenterol 13 (1999) 129-133
Cunningham L.S., and Kelsey J.L. Epidemiology of musculoskeletal impairments and associated disability. Am J Public Health 74 (1984) 574-579
Langman M., Kahler K.H., Kong S.X., Zhang Q., Finch E., Bentkover J.D., et al. Drug switching patterns among patients taking non-steroidal anti-inflammatory drugs: a retrospective cohort study of a general practitioners database in the United Kingdom. Pharmacoepidemiol Drug Saf 10 (2001) 517-524
Martin R.M., Biswas P., and Mann R.D. The incidence of adverse events and the risk factors for upper gastrointestinal disorders associated with meloxicam use amongst 19,087 patients in general practice in England: cohort study. Br J Clin Pharmacol 50 (2000) 35-42
Saturno P.J., Palmer R.H., and Gascon J.J. Physician attitudes, self-estimated performance and actual compliance with locally peer-defined quality evaluation criteria. Int J Qual Health Care 11 (1999) 487-496
Gabriel S.E., Jaakkimainen L., and Bombardier C.S. Risk for serious gastrointestinal complications related to the use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med 115 (1991) 787-796
Hansen J.M., Hallas J., Lauritsen J.M., and Bytzer P. Non-steroidal anti-inflammatory drugs and complications: a risk factor analysis for clinical decision-making. Scand J Gastroenterol 31 (1996) 126-130
Richy F., Bruyère O., Ethgen O., Rabenda V., Bouvenot G., Audran M., et al. Time-dependent risk of gastrointestinal complications induced by NSAIDS use: a consensus statement using meta-analytic approach. Ann Rheum Dis 63 7 (2004) 759-766
Pettitt D., Goldstein J.L., McGuire A., Schwartz J.S., Burke T., and Maniadakis N. Overview of the arthritis cost consequence evaluation system (ACCES): a pharmacoeconomic model for celecoxib. Rheumatology (Oxford) 39 Suppl 2 (2000) 33-42
MacDonald T.M., Morant S.V., Robinson G.C., Shield M.J., McGilchrist M.M., Muray F.E., et al. Association of upper gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs with continued exposure: cohort study. BMJ 315 (1997) 1333-1337
Singh G. Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. Am J Med 105 (1998) 31S-38S
Clinard F., Bardou M., Sgro C., Lefevre N., Raphael F., Paille F., et al. Non-steroidal anti-inflammatory and cytoprotective drug co-prescription in general practice. A general practitioner-based survey in France. Eur J Clin Pharmacol 57 (2001) 737-743
Schnitzer T.J., Kong S.X., Mavros P.P., Straus W.L., and Watson D.J. Use of nonsteroidal anti-inflammatory drugs and gastroprotective agents before the advent of cyclooxygenase-2-selective inhibitors: analysis of a large United States claims database. Clin Ther 23 (2001) 1984-1998
Sturkenboom M.C., Romano F., Simon G., Correa-Leite M.L., Villa M., Nicolosi A., et al. The iatrogenic costs of NSAID therapy: a population study. Arthritis Rheum 47 (2002) 132-140